Simon Mølgaard
CEO
Teitur Trophics
Teitur Trophics develops cyclic peptides targeting Sortilins receptors to create therapeutics for neurodegenerative diseases such as Huntington’s, Parkinson’s, and Frontotemporal Dementia. The company addresses the lack of effective treatments for over 200 million patients worldwide suffering from progressive neurodegeneration that impacts memory, movement, and quality of life.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$31.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Over 200 million patients worldwide suffer from neurodegenerative diseases like Huntington’s, Parkinson’s, and Frontotemporal Dementia, which progressively impair memory, movement, and overall quality of life. Currently, there are no effective treatments to prevent the relentless progression of these debilitating conditions.
Solution
Teitur Trophics is developing novel cyclic peptides that target Sortilin receptors to treat and potentially prevent neurodegenerative diseases. These peptides have the potential to address key pathologies across several neurodegenerative disorders, offering a disease-modifying approach. The company's ambition is to create new treatments that improve the lives of patients suffering from these conditions, helping them live longer, better, and happier lives by restoring brain functions.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, their families, and healthcare providers specializing in neurology.
Features
- Cyclic peptides targeting Sortilin receptors
- Focus on Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia
- Potential for disease modification rather than just symptom management